Clinical Trials Browser

Phase 1/2 × Prostatic Neoplasms × cemiplimab × Clear all

NCT04989946 2026-01-28

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03367819 2022-05-16

Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

Phase 1/2 Terminated

44 enrolled 24 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms